Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- German Low Grade Lymphoma Study Group
- Registration Number
- NCT00016887
- Locations
- 🇧🇪
AZ Sint-Jan, Brugge, Belgium
🇮🇹Ospedale Civile Alessandria, Alessandria, Italy
Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Commissie Voor Klinisch Toegepast Onderzoek
- Target Recruit Count
- 340
- Registration Number
- NCT00012051
- Locations
- 🇳🇱
Academisch Medisch Centrum at University of Amsterdam, Amsterdam, Netherlands
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
🇳🇱HagaZiekenhuis - Locatie Leyenburg, 's-Gravenhage, Netherlands
Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 260
- Registration Number
- NCT00025064
- Locations
- 🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom
🇬🇧Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom
🇬🇧Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
Chemotherapy and Surgery Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Neuroblastoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Registration Number
- NCT00024193
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
- Conditions
- Locations
- 🇩🇪
Carl - Thiem - Klinkum Cottbus, Cottbus, Germany
🇩🇪Klinikum Lippe - Detmold, Detmold, Germany
🇩🇪Praxis am Evangelischen Krankenhaus Bethanien, Iserlohn, Germany
Chemotherapy Followed by Surgery and Radiation Therapy With or Without Stem Cell Transplant in Treating Patients With Relapsed or Refractory Wilms' Tumor or Clear Cell Sarcoma of the Kidney
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 75
- Registration Number
- NCT00025103
- Locations
- 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
🇬🇧Great Ormond Street Hospital for Children, London, England, United Kingdom
🇬🇧Southampton General Hospital, Southampton, England, United Kingdom
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 147
- Registration Number
- NCT00040937
- Locations
- 🇺🇸
Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States
🇺🇸Community Medical Center, Missoula, Montana, United States
🇺🇸Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 77
- Registration Number
- NCT00004088
- Locations
- 🇺🇸
Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00003199
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/Puget Sound Oncology Consortium, Seattle, Washington, United States
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00014508
- Locations
- 🇺🇸
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸CCOP - Northern New Jersey, Hackensack, New Jersey, United States
🇺🇸Baptist Cancer Institute - Jacksonville, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.